In the future, we will continue to focus on the regulatory mechanism of TRIM21 in NKAPL and develop NKAPL methylation inhibitors and NKAPL-targeted delivery systems for combination therapy for NSCLC. Here, NKAPL is linked to non-small cell lung carcinoma.